Summary The expression of retinoblastoma (Rb), c-Myc and Bcl-2 proteins was studied by immunohistochemical methods in 104 cases of renal adenocarcinoma. One tumour was completely negative for Rb protein and altered expression pattern was detected in 36% of cases. A low fraction of Rb-positive nuclei was related to high grade (P = 0.016) and high mitotic index (P = 0.012). Twenty-eight per cent of the tumours expressed c-Myc in cancer cell nuclei and 87% showed cytoplasmic positivity. Cytoplasmic expression of c-Myc was related to high grade (P= 0.002), while nuclear expression of c-Myc was related to small tumour diameter (P = 0.034), low T category (P = 0.04), low mitotic index (P = 0.019) and expression of c-ErbB-2 (P = 0.0007). Overexpression of c-myc predicted favourable outcome in MO tumours (P = 0.0157). Bcl-2 was expressed in 20% of tumours and it was related to small tumour size (P<0.0001), low T category (P<0.0001), lack of venous invasion (P= 0.008), node negativity (P = 0.015) and absence of metastasis (P = 0.017). In multivariate analysis the expression of Rb, Bcl-2 and c-Myc had no independent prognostic value over T category (P<0.001), mitotic index (P = 0.008) and combined nuclear grade (P = 0.056).
The prognosis of renal adenocarcinoma depends on the primary tumour size, histological features and proliferation rate of tumour cells (Syrjanen and Hjelt, 1978a; Kinouchi et al., 1989; Di Silvero et al., 1992; Eskelinen et al., 1993; Lipponen et al., 1994) . Recent results show that mutations rarely occur in the c-erbB-2 and p53 genes in renal adenocarcinoma (Tal et al., 1988; Ogawa et al., 1992; Makos et al., 1993; Lipponen et al., 1994) and they probably have no independent prognostic value (Lipponen et al., 1994) . Mutations in tumour-suppressor genes p53 and Rb are common in several types of neoplasms, and they also relate to prognosis (Cordon-Cardo et al., 1992; Silvestrini et al., 1993) . The prognostic significance of Rb gene mutations is mainly unexplored in renal adenocarcinoma (Ishikawa et al., 1991) ; the results concerning Rb expression in other neoplasms suggest that mutations in the Rb gene have prognostic significance (Cordon-Cardo et al., 1992) . The growth rate of neoplasms depends on the proliferation and death rates of cancer cells, which in part may represent programmed cell death or apoptosis (Allan et al., 1992; Sachs and Lotem, 1993) . Mutations in the bcl-2 gene inhibit apoptosis (Sachs and Lotem, 1993; Schena et al., 1993) which may contribute to the development of tumours and modify their clinical behaviour (Allan et al., 1992; Sachs and Lotem, 1993; Schena et al., 1993) . Alterations in the c-myc gene family also regulate cell proliferation and apoptosis (Evan and Littlewood, 1993; Koskinen and Alitalo, 1993; Sachs and Lotem, 1993) . Accordingly bc1-2 and c-myc genes are in a central position in regulating the direction of the cell cycle towards apoptosis or mitosis. The present study was designed to analyse the prognostic role of c-myc, bcl-2 and Rb gene expression by immunohistochemical methods in renal adenocarcinoma. This combination of genes was selected because these genes play an important role in regulating the growth rate of tumours. Table I .
Patients and methods

Patients
Histological grading of tumours was completed using the nuclear grading system (three grades) (Syrjanen and Hjelt, 1978a) as well as the combined nuclear grading (six grades), as detailed previously (Syrjanen and Hjelt, 1978b staining method has been described in detail previously (Lipponen et al., 1994) . However, the routine method was modified when Rb and Bcl-2 proteins were detected. To detect Rb protein, the sections were pretreated with 0.5% pepsin in 0.1% 864 oft p53 and c-ErbB-2 immunohistochemistry These oncoproteins were detected as described previously (Lipponen et al., 1994) . In detecting p53 protein, polyclonal rabbit anti-human p53 antibody CM 1 (Novocastra Laboratories) at a dilution of 1:1200 was used. To detect c-ErbB-2 oncoprotein, the slides were treated with 0.5% pepsin in 0.01 N hydrochloric acid for 60 min before adding the blocking normal horse serum. The monoclonal mouse anti-human c-ErbB-2 antibody (NCL-1) (Triton Biosciences, Alameda, CA, USA) diluted to 1:30 was used in detecting c-ErbB-2 protein.
Statistical methods
The statistical calculations were done by using the SPSS-X program; the statistical tests used are indicated in the results when appropriate. The univariate survival analysis (log-rank analysis, SPSS-X) was based on the life table method with the statistics of Lee and Desu (1972) . Multivariate survival analysis was done with the BMDP (2L) package (Cox, 1972) in a stepwise manner, and only deaths due to renal cancer were used as events. Multivariate analysis included only cases for which a complete set of data was available. The year of treatment, patient age and sex were included in the analysis to control for their possible confounding effects. (Figure ic ). Nuclear and cytoplasmic expression showed significant intra-tumour variation and usually the invasive areas were intensively positive. Expression of c-Myc in the cytoplasm was positively correlated to nuclear grade (Table III) and combined nuclear grade (P = 0.002). Nuclear expression of c-Myc was not related to sex, age, grade, NM classification or expression of p53 (for all P> 0.2). there was a positive correlation between the expression of c-ErbB-2 but a negative correlation between tumour diameter, T category and nuclear expression of c-Myc (Table  IV) . Tumours with a M/V index <7 mm-2 had a higher fraction of positive nuclei than tumours with a M/V index > 7 mm-2 (4.2% vs 1.0%, t = 2.4, P = 0.019). In survival analysis cytoplasmic positivity indicated better prognosis in MO tumours (Figure 2 ).
Expression of Bcl-2
Bcl-2 was weakly expressed in normal renal tubular cells (nuclear envelope and cytoplasm). Bcl-2 was expressed (cytoplasm and nucleus) in 21/104 (20%) of tumours, and intra-tumour variation was present. Expression of Bcl-2 was significantly related to tumour size, venous invasion (P = 0.008) and TNM classification (Table V) (Ishikawa et al., 1991; Geradts et al., 1994) . Usually deletions result in total loss of Rb protein expression while point mutations may result in lowered expression intensity of the Rb protein (Geradts et al., 1994) .
Altered expression of Rb protein was found in 36% of cases, which is close to the previously reported figures in other neoplasms (Logethesis et al., 1992) . Previous reports also suggest a significant relationship between altered Rb expression, grade and stage in bladder cancer (Cordon-Cardo et al., 1992; Xu et al., 1993) , whereas in this study only grade and mitotic index were related to expression of Rb. Also, opposite results exist since, according to one recent study, abnormal Rb protein expression is not related to cell proliferation as measured by proliferating cell nuclear antigen immunolabelling (Logethesis et al., 1992) . Expression of Rb has been related to prognosis in some neoplasms (Logathesis et al., 1992; Cordon-Cardo et al., 1992) , while in this analysis reduced expression of Rb was without prognostic significance and the prognostic results in breast cancer are similar (Sawan et at., 1992) .
Myc proteins are normally bound to nuclear matrix proteins (Waitz and Loidl, 1991) , and analyses based on frozen tissue sections have demonstrated Myc proteins usually in the cell nucleus (Kotake et al., 1990; Melhem et al., 1992) . Analyses based on paraffin-embedded tissues have found Myc positivity in the cytoplasm and in the nucleus (Kotake et al., 1990; Melhem et al., 1992) . This altered cellular distribution is probably related to dislocation of Myc proteins related to fixation and processing of the tissue sections, or they may be less tightly associated with nucleus in malignant cells.
Amplification or overexpression of c-myc has been previously related to cell proliferation in human neoplasms (Munzel et al., 1991; Melhem et al., 1992; Yamaguchi et al., 1992) albeit the results are variable. In this study cytoplasmic expression of c-myc was independent of mitotic index while nuclear expression was related to low proliferation rate. These results suggest that the relationship between cell proliferation and expression of c-myc is not clear-cut and other regulatory mechanisms are probably involved. The present results confirm previous results in that poor histological differentiation and expression of c-myc are interrelated (Kotake et al., 1990; Yamaguchi et al., 1992; Lanigan et al., 1993) . Stage of disease and expression of Myc were not interrelated, which is at variance with previous results in renal adenocarcinomas (Lanigan et al., 1993) .
The prognostic significance of the overexpression or amplification of c-myc is disputable in neoplasms (Erisman et al., 1988; Berns et al., 1992) . Our survival analysis suggests that overexpression of c-myc is related to favourable outcome. This is probably related to small tumour size to which overexpression of c-myc was associated. In multivariate analysis expression of c-myc had no independent prognostic value which is in agreement with the recent results reported by Lanigan et al. (1993) .
Ultrastructural studies have shown that Bcl-2 immunoreactivity is localised to mitochondrial outer circumference, to nuclear envelope and to a lesser degree to cell membranes (Nguyen et al., 1993; de Jong et al., 1994) , which is in accord with the current results. The bct-2 gene product regulates programmed cell death, and a number of studies suggest that Bcl-2 is involved in the selection and maintenance of longliving cells and rescuing them from apoptotic cell death (Hanada et al., 1993) . Bcl-2 protein was weakly expressed in normal renal tissue and commonly also in well-differentiated small tumours, while the expression was reduced in tumours that exhibited features related to high malignancy. These results are in full agreement with the results of Doglioni et al. (1994) in breast cancer. However, the expression of Bcl-2 was not related to prognosis.
In summing up the results of this analysis, we suggest that expression of Rb, c-Myc and Bcl-2 proteins is related to cell proliferation and differentiation of tumours in renal adenocarcinoma. Expression of these proteins may therefore have a role in determining tumour behaviour, but further work is clearly required to elucidate this.
